Fresenius Medical Care AG (NYSE:FMS) has been given a consensus recommendation of “Buy” by the fifteen analysts that are covering the firm. Seven investment analysts have rated the stock with a hold rating and eight have issued a buy rating on the company. The average 12-month price objective among brokerages that have issued a report on the stock in the last year is $45.33.

A number of research analysts have recently weighed in on FMS shares. HSBC reissued a “hold” rating on shares of Fresenius Medical Care AG in a report on Tuesday, October 18th. Citigroup Inc. raised Fresenius Medical Care AG from a “neutral” rating to a “buy” rating in a report on Tuesday, September 6th. DZ Bank AG reissued a “neutral” rating on shares of Fresenius Medical Care AG in a report on Thursday. RBC Capital Markets reissued a “sector perform” rating and issued a $44.00 price objective (up from $41.00) on shares of Fresenius Medical Care AG in a report on Tuesday, November 1st. Finally, SunTrust Banks Inc. set a $48.00 price objective on Fresenius Medical Care AG and gave the company a “buy” rating in a report on Thursday, October 13th.

Fresenius Medical Care AG (NYSE:FMS) opened at 40.10 on Tuesday. The stock has a market capitalization of $24.55 billion, a PE ratio of 20.95 and a beta of 0.58. The company has a 50-day moving average price of $42.00 and a 200-day moving average price of $43.36. Fresenius Medical Care AG has a 12-month low of $38.71 and a 12-month high of $47.52.

Fresenius Medical Care AG (NYSE:FMS) last announced its quarterly earnings data on Thursday, October 27th. The company reported $1.09 earnings per share for the quarter, beating analysts’ consensus estimates of $0.52 by $0.57. The business had revenue of $4.60 billion for the quarter, compared to analyst estimates of $4.55 billion. Fresenius Medical Care AG had a return on equity of 10.56% and a net margin of 6.67%. The company’s revenue was up 8.7% on a year-over-year basis. During the same period in the prior year, the company earned $0.93 earnings per share. Analysts expect that Fresenius Medical Care AG will post $2.02 earnings per share for the current fiscal year.

A number of institutional investors have recently modified their holdings of FMS. Cambiar Investors LLC increased its position in shares of Fresenius Medical Care AG by 5.2% in the second quarter. Cambiar Investors LLC now owns 2,333,733 shares of the company’s stock worth $101,681,000 after buying an additional 114,840 shares in the last quarter. Mariner Wealth Advisors LLC acquired a new position in shares of Fresenius Medical Care AG during the first quarter worth about $331,000. JPMorgan Chase & Co. increased its position in shares of Fresenius Medical Care AG by 1.5% in the first quarter. JPMorgan Chase & Co. now owns 134,551 shares of the company’s stock worth $5,930,000 after buying an additional 1,950 shares in the last quarter. Rothschild Asset Management Inc. acquired a new position in shares of Fresenius Medical Care AG during the second quarter worth about $340,000. Finally, Independent Portfolio Consultants Inc. increased its position in shares of Fresenius Medical Care AG by 2.2% in the second quarter. Independent Portfolio Consultants Inc. now owns 6,155 shares of the company’s stock worth $268,000 after buying an additional 130 shares in the last quarter. Institutional investors own 2.50% of the company’s stock.

About Fresenius Medical Care AG

Fresenius Medical Care AG & Co KGaA (FMC AG & CO. KGAA) is a kidney dialysis company. The Company provides dialysis care and related services to persons suffering from end stage renal disease (ESRD), as well as other healthcare services. The Company operates through four segments: North America, Europe, Middle East, Africa (EMEA), Asia-Pacific and Latin America.

5 Day Chart for NYSE:FMS

Receive News & Stock Ratings for Fresenius Medical Care AG Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Fresenius Medical Care AG and related stocks with our FREE daily email newsletter.